Special notice
BioMerieux rapid microbial identification (ID) and antibiotic susceptibility testing
HT940827Q0003
Defense Health Agency (Dha), Defense Health Agency. In-Vitro Diagnostic Substance Manufacturing.
Response deadline
October 12, 2026 at 6:00 PM EDT
Closed 19 days ago. Posted October 8, 2026. Scheduled to archive October 27, 2026.
Get the next one like this from Defense Health Agency (Dha) by email, the day it is posted.Find my opportunities
This one closed 19 days ago
13 like it are open now in in-vitro diagnostic substance manufacturing
- Blood Bank Reagents
Department of Veterans Affairs, 257-Network Contract Office 17
Sources soughtNAICS 325413Anywhere in the US36C25727Q0065Closes in 5 daysNov 5 - BPA - Consumable Supplies for Terumo Trima Accel Blood Collection systems
Defense Health Agency (Dha), Army Med Res Acq Activity
SolicitationSDVOSBNAICS 325413Anywhere in the USHT942627QE003Closes in 6 daysNov 6 - NOI - DNA Sequencing of Bone Marrow Failure Syndro
National Institutes of Health, National Institutes of Health Olao
Combined synopsis and solicitationNAICS 325413Anywhere in the US75N98027Q00027Closes in 2 daysNov 2
Description
As published on SAM.gov.
NOTICE OF INTENT TO SOLE SOURCE
The Wilford Hall Ambulatory Surgical Center, Lackland MDTS/Laboratory Flight’s intends to award a sole source contract with bioMérieux, Inc/, to procure a fully automated microbiology instrument that performs rapid microbial identification (ID) and antibiotic susceptibility testing via utilization systems VITEK 2 60, AST, VC-VITEK, and VC-BACT/ALERT VIRTUO systems with MAESTRIA data management. which includes all necessary reagents and comprehensive maintenance services for the Medical Treatment Facility (MTF) Wilford Hall. The Period of Performance is for one (1) year beginning 1 November 2026 through 31 October 2027 in the amount of $135.373.31.
The contractor shall deliver the following crucial elements: Vitek2 and BacT/ALERT 3D with Myla Software, 3.1. System Capabilities - Fully automated immunoassay platform utilizing a solid-phase methodology for allergen-specific IgE detection. Capability to perform simultaneous testing of multiple allergens and allergen components from a single patient sample, VTK2 20CARDS GP, GN, YST, NH, ANC, AST-N809, GP67, YS09, VTK2 PIP/DIL. Quantitative measurement of allergen-specific IgE antibodies. Minimal interference from othermunoglobulins (e.g., IgG). • Dimensions: (H/W/D): 215 x 183 x 105 cm, 3.2. Performance Requirements. High-throughput capability supporting large-scale laboratory operations. Ability to produce 240 tests per hour with first result available in 100 minutes followed by one every 15 seconds.
Interested sources with the demonstrated capability to meet all of the technical requirements outlined in this notice are invited to submit, in writing. Responses must include clear and convincing evidence that competition would be beneficial to the Government and would not be cost or schedule prohibitive. Respondents are responsible for appropriately marking any proprietary information. Responses will not be returned.
This synopsis/notice of intent to sole source is issued in accordance with Federal Acquisition Regulation (FAR) Revolutionary FAR Overhaul (RFO) 5.101 and 12.102 and will be posted for 5 days.
Response Due Date: October 12, 2026 by 12:00 PM (CST)
Submit to: Contracting Officer: Joe D. Wells at joe.d.wells3.civ@health.mil.
Publications
Every notice SAM.gov issued under this solicitation number, oldest first. Each is a separate record on SAM.
October 8, 2026
Special notice
Due October 12, 2026 at 6:00 PM EDT. SAM.gov, notice ff4a01b81b1b4c0b86df9d561c38c0a1
1 revisions on SAM
- October 8, 2026: publish, special notice
Points of contact
- Dulce Baresdulce.i.bares.civ@health.mil
- Joe Wellsjoe.d.wells3.civ@health.mil